SUPPLEMENTAL MATERIAL

Study population

Inclusion criteria

- Men or women 18-70 years of age
- HbA1C < 5.8%
- Able to provide written informed consent

Exclusion criteria

- Pregnancy or lactation
- Diagnosed with diabetes mellitus
- Weight change ≥ 5 % within 3 months prior to admission to the study
- Has taken any weight loss medications within 3 months prior to admission to the study
- Immunocompromised status, including a debilitated state or malignancy
- Active liver, renal, thyroid diseases
- Frequent alcoholic consumption more than twice a week; with beer > 360 mL, alcohol > 45 mL, wine > 150 mL for female, or beer > 720 mL, whisky > 90 mL, wine > 300 mL for male each time
- Has gastrointestinal symptoms such as nausea, vomiting, loss of appetite, premature satiety, diarrhea, or chronic constipation
- Lack of ability or willingness to give informed consent
- Taken any medications than might cause weight loss or weight gain such as corticosteroid, antidepressant, antipsychotics, oral contraceptive pills < 8 weeks or change the dose of these medication with 8 week prior to admission
- Patients in cardiac Class II, III or IV.
- Patients who have had renal transplants or are currently receiving renal dialysis.
- Patients with the diagnosis of psychosis.
- Patients with known HIV infection.

Franchi F, *et al. BMJ Open Diab Res Care* 2021; 9:e001939. doi: 10.1136/bmjdrc-2020-001939

- Patients with history of malignancy within the last one year with the exception of localized skin cancers.
- Patients with significant clinical signs or symptoms of liver disease, acute or chronic hepatitis, or aspartate transaminase (AST or SGOT) greater than three times the upper reference range limit.
- Patients with clinical signs or symptoms of drug or alcohol abuse.
- Patients with a life expectancy of less than 5 years.
- Patients with any cognitive impairment diagnosed previously
- Patients with a serum creatinine greater 1.5 mg/dl.
- Patients exhibiting serious non-compliance with prescribed diet or drug therapy.
- Patients who are currently participating or have participated in a medical, surgical, or pharmaceutical investigation in which an investigational new drug was dispensed to the patient within the last 30 days.
- Patients with a body mass index (B.M.I.) greater than 40 kg/m^2.
- Patients with a body mass index (B.M.I.) less than 20 kg/m^2.
- Any situation which precludes the patient from following and completing the protocol.
- Patients with known hemoglobinopathy or chronic anemia with hemoglobin <10gm/dL

Franchi F, *et al. BMJ Open Diab Res Care* 2021; 9:e001939. doi: 10.1136/bmjdrc-2020-001939

Supplemental Figure 1. Comparison of plasma glucose levels among placebo and different D-allulose doses according to race (White vs. African American). Bars represent mean. P-values represent the treatment by race interaction and the total effect of race on plasma glucose at each time point. AA: African American; W: White.



Supplemental Figure 2. Comparison of insulin levels among placebo and different D-allulose doses according to race (White vs. African American). Bars represent mean. P-values represent the treatment by race interaction and the total effect of race on insulin at each time point. AA: African American; W: White.